Cefepime for Urinary Tract Infections
Cefepime is indicated for hospitalized patients with uncomplicated or complicated UTIs, including pyelonephritis, and should be dosed at 0.5-1 g IV every 12 hours for mild-to-moderate infections or 2 g IV every 12 hours for severe infections, administered over 7-10 days. 1
Clinical Indications
Cefepime is specifically reserved for parenteral therapy in hospitalized patients with UTIs, not for simple outpatient cystitis. According to the 2024 European Association of Urology guidelines, cefepime is recommended as an extended-spectrum cephalosporin option for patients with uncomplicated pyelonephritis requiring hospitalization 2. The guidelines note that while lower doses have been studied, higher doses are recommended for optimal outcomes 2.
When to Use Cefepime:
- Hospitalized patients with complicated or severe UTIs
- Pyelonephritis requiring intravenous therapy
- Patients with risk factors for resistant organisms (though not as first-line for multidrug-resistant pathogens)
- When oral fluoroquinolones or cephalosporins are inappropriate or have failed
- Pediatric patients (2 months to 16 years) with serious UTIs at 50 mg/kg/dose every 12 hours 1
FDA-Approved Dosing Regimens
The FDA label provides clear dosing stratification based on infection severity 1:
Adults with Normal Renal Function (CrCL >60 mL/min):
- Mild-to-moderate uncomplicated or complicated UTI: 0.5-1 g IV every 12 hours for 7-10 days
- Severe uncomplicated or complicated UTI: 2 g IV every 12 hours for 10 days
- Administration: Infuse intravenously over approximately 30 minutes
Renal Dose Adjustments:
Critical caveat: Failure to adjust doses in renal impairment can lead to neurotoxicity 1. For patients with CrCL ≤60 mL/min, dosing must be reduced:
- CrCL 30-60 mL/min: Reduce frequency to every 24 hours
- CrCL 11-29 mL/min: Further dose reduction required (e.g., 1 g every 24 hours for severe UTI)
- CrCL <11 mL/min: 500 mg every 24 hours for severe UTI
- Hemodialysis: 1 g on day 1, then 500 mg every 24 hours, administered after dialysis 1
Clinical Context and Positioning
Not First-Line for Uncomplicated Pyelonephritis:
The EAU guidelines clearly state that fluoroquinolones and oral cephalosporins are the only agents recommended for oral empiric treatment of uncomplicated pyelonephritis 2. Cefepime is positioned for patients requiring hospitalization and IV therapy.
Antimicrobial Stewardship Considerations:
The guidelines emphasize that carbapenems and novel broad-spectrum agents should only be considered in patients with early culture results indicating multidrug-resistant organisms 2. Cefepime occupies a middle ground—broader than third-generation cephalosporins like ceftriaxone but narrower than carbapenems. The choice should be based on local resistance patterns 2.
Clinical Efficacy Data:
Research demonstrates that cefepime achieves clinical cure rates of 92-93% and bacteriological eradication rates of 85-95% in serious UTIs 3, 4. In pediatric populations, favorable clinical and microbiologic responses occur in >95% of cases 5. Recent data on cefepime-taniborbactam combinations show even higher efficacy (70.6% composite success) against resistant organisms 6, though this combination is investigational.
Common Pitfalls to Avoid
Using cefepime for simple cystitis: This is inappropriate antimicrobial stewardship—reserve for hospitalized patients with severe or complicated infections
Inadequate renal dose adjustment: This is the most critical error, as unadjusted doses in renal impairment can cause neurotoxicity including encephalopathy, seizures, and myoclonus 1
Underdosing severe infections: The FDA label specifically notes that while lower doses were studied, higher doses (2 g every 12 hours) are recommended for severe UTIs 1
Ignoring local resistance patterns: Empiric selection must account for local susceptibility data, particularly for Pseudomonas aeruginosa coverage 2
Prolonged empiric use without culture data: Obtain urine cultures before initiating therapy and adjust based on susceptibility results
Pediatric Considerations
For children 2 months to 16 years with serious UTIs including pyelonephritis, dose at 50 mg/kg every 12 hours (maximum not to exceed adult dosing) 1. The same renal adjustment principles apply, though pediatric-specific renal impairment data are limited 1.